Get started
Author

Lorena Pérez-Amill

Observed names: L. Perez-Amill, Lorena Perez - Amill, Lorena Perez Amill, Lorena Perez-Amill, Perez-Amill, L., Pérez Amill, Lorena, Pérez-Amill, Lorena
Observed institutions: Josep Carreras Leukaemia Research Institute, Hospital Clínic de Barcelona, CaixaBank, Fundació Clínic per a la Recerca Biomèdica, Consorci Institut D'Investigacions Biomediques August Pi I Sunyer, Barcelona Activa, Fundació de Recerca Clínic Barcelona-Institut d’Investigacions Biomèdiques August Pi i Sunyer, Universitat de Barcelona
ORCID: 0000-0003-0674-4660
Observed ORCID: 0000-0003-0674-4660
OpenAlex ID: A5079200899
Development of a Novel Anti-CD19 Chimeric Antigen Receptor: A Paradigm for an Affordable CAR T Cell Production at Academic Institutions
2018 · Maria Castella, Anna Boronat, et al. · Molecular Therapy — Methods & Clinical Development · 135
PDF
Natural Killer Cells: Angels and Devils for Immunotherapy
2017 · Beatriz Martín-Antonio, Guillermo Suñe, et al. · International Journal of Molecular Sciences · 75
PDF
NK cells enhance CAR-T cell antitumor efficacy by enhancing immune/tumor cells cluster formation and improving CAR-T cell fitness
2021 · Mireia Bachiller, Lorena Perez-Amill, et al. · Journal for ImmunoTherapy of Cancer · 62
PDF
First report of CART treatment in AL amyloidosis and relapsed/refractory multiple myeloma
2021 · Aina Oliver-Caldes, Raquel Jiménez, et al. · Journal for ImmunoTherapy of Cancer · 51
PDF
Preclinical development of a humanized chimeric antigen receptor against B cell maturation antigen for multiple myeloma
2020 · Lorena Perez-Amill, Guillermo Suñe, et al. · Haematologica · 45
PDF
Engineered T cells secreting anti-BCMA T cell engagers control multiple myeloma and promote immune memory in vivo
2024 · Laura Díez-Alonso, Aïda Falgas, et al. · Science Translational Medicine · 38
Advancing CART therapy for acute myeloid leukemia: recent breakthroughs and strategies for future development
2023 · Lorena Pérez-Amill, Àlex Bataller, et al. · Frontiers in Immunology · 26
PDF
Natural Killer Cells in Immunotherapy: Are We Nearly There?
2020 · Mireia Bachiller, Anthony M. Battram, et al. · Cancers · 26
PDF
Loss of the Immune Checkpoint CD85j/LILRB1 on Malignant Plasma Cells Contributes to Immune Escape in Multiple Myeloma
2018 · Ester Lozano, Tania Díaz, et al. · The Journal of Immunology · 26
Biomarkers of Efficacy and Safety of the Academic BCMA-CART ARI0002h for the Treatment of Refractory Multiple Myeloma
2024 · Aina Oliver-Caldes, Marta Español-Rego, et al. · Clinical Cancer Research · 21
Extracellular NK histones promote immune cell anti-tumor activity by inducing cell clusters through binding to CD138 receptor
2019 · B. Martín-Antonio, G. Suñe, et al. · Journal for ImmunoTherapy of Cancer · 19
PDF
Adoptive transfer of NK cells engineered with a CD5-based chimeric antigen receptor (SRCD5CAR) to treat invasive fungal infections
2025 · María Velasco-de-Andrés, Cristina Català, et al. · Molecular Therapy · 14
Microbiota Shape Metabolic and Immune Determinants of CAR-T Therapy and Correlate with Outcomes in Myeloma
2025 · Mireia Uribe-Herranz, Aina Oliver-Caldés, et al. · Blood Cancer Discovery · 12
CD84: A Novel Target for CAR T-Cell Therapy for Acute Myeloid Leukemia
2022 · Lorena Pérez-Amill, Mercedes Armand-Ugon, et al. · Blood · 12
CAR-T cell therapy, a door is open to find innumerable possibilities of treatments for cancer patients
2018 · Lorena Perez - Amill, Berta Marzal, et al. · Turkish Journal of Hematology · 12
PDF
A novel chimeric antigen receptor T-cell therapy targeting CD84 for the treatment of acute myeloid and T-cell lymphoblastic leukemias
2025 · Lorena Pérez-Amill, Mercedes Armand-Ugón, et al. · Leukemia · 9
PDF
ARI0002h (Cesnicabtagene Autoleucel), an Academic Point-of-Care B-Cell Maturation Antigen (BCMA)-Directed Chimeric Antigen Receptor (CAR) T-Cell Strategy: Activity and Safety after Fractionated Initial Therapy and Booster Dose in 60 Patients with Relapsed/Refractory Multiple Myeloma
2023 · Aina Oliver-Caldes, Veronica Gonzalez-Calle, et al. · Blood · 7
Bicistronic CAR T Cell against BCMA and CD229 Effectively Controls Myeloma Even When BCMA Expression Is Limited
2025 · Luis Gerardo Rodríguez-Lobato, Oriol Cardús, et al. · Cancer Immunology Research · 6
A Quantitative Approach to Potency Testing for Chimeric Antigen Receptor-Encoding Lentiviral Vectors and Autologous CAR-T Cell Products, Using Flow Cytometry
2025 · Juan José Mata-Molanes, Leticia Alserawan, et al. · Pharmaceutics · 6
TIGIT blockade in the context of BCMA-CART cell therapy does not augment efficacy in a multiple myeloma mouse model
2025 · Aina Oliver-Caldes, Joan Mañe Pujol, et al. · OncoImmunology · 4
PDF
Correlative Biological Studies Related to the Response, Peak and Persistence of ARI0002h, an Academic BCMA-Directed CAR-T Cell, with Fractionated Initial Infusion and Booster Dose for Patients with Relapsed and/or Refractory Multiple Myeloma (RRMM)
2021 · Aina Oliver-Caldés, Marta Español-Rego, et al. · Blood · 3
Bicistronic CAR T Cell Against CD229 and BCMA Effectively Controls Multiple Myeloma
2022 · Luis Gerardo Rodríguez-Lobato, Oriol Cardus, et al. · Blood · 1
Natural Killer Cells Transfer Antimicrobial and Antitumoral Histone H2AZ to Kill Multiple Myeloma Cells Contributing to Transmissible Cytotoxicity
2016 · Beatriz Martin-Antonio, Guillermo Suñe, et al. · Blood · 1
Clinical and Mechanistic Insights into Non-ICANS Neurotoxicity Following BCMA CAR T-Cell Therapy
2026 · Leonie Mueller-Jensen, Serena Kwek, et al. · Neurology
PDF
CD84 Expression Across Disease Stages and Leukemic Subpopulations in Acute Myeloid Leukemia
2026 · Beatriz Martín-Herreros, Lourdes Cordón, et al. · Cancers
Works count: 127
Citation count: 611
H-index: 12
I10-index: 15
Year
Topic
Type